Rituximab plus telitacicept for ANCA vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old, and can be any gender
- You have been newly diagnosed or are in a relapse of GPA or MPA, based on 2022 ACR/EULAR classification
- Your vasculitis is severe and actively causing problems right now (meets 2021 ACR/VF criteria)
- Your PR3-ANCA test is positive (at diagnosis or during your disease)
- You have not previously stopped rituximab due to side effects or intolerance
- You are not pregnant (or planning pregnancy in the next 2 years) and you do not have certain serious infections or major organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.